[EN] N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE APPARENTÉS À LA N-ACYLPIPÉRIDINE ÉTHER TROPOMYOSINE
申请人:PFIZER LTD
公开号:WO2015092610A1
公开(公告)日:2015-06-25
The present invention relates to compounds of Formula (I) described herein and their pharmaceutically acceptable salts, and their use in medicine, in particular as Trk antagonists.
Chemoselective acylation of benzimidazoles with phenylacetic acids under different Cu catalysts to give fused five-membered N-heterocycles or tertiary amides
作者:Shaoyu Mai、Yingwei Zhao、Qiuling Song
DOI:10.1039/c6ob01167e
日期:——
bond formation via a copper-catalyzed aerobic oxidative decarboxylative tandem protocol was realized. The phenylacetic acids which contain ortho-X (X = F or Br) on the aromatic ring will render a fused five-membered heterocycle via a tandem aromatic nucleophilic substitution and aerobic oxidative decarboxylative acylation at the C(sp2)–H bond of benzimidazoles under the Cu(OAc)2/K2CO3/BF3·Et2O catalytic
通过铜催化的好氧氧化脱羧串联方案实现了C–N键的形成。在芳环上含有邻-X(X = F或Br)的苯乙酸将通过串联芳族亲核取代和苯并咪唑的C(sp 2)-H键上的好氧氧化脱羧酰化反应,形成稠合的五元杂环在Cu(OAc)2 / K 2 CO 3 / BF 3 ·Et 2 O催化体系下,以CuBr为催化剂,吡啶为碱,发生N-酰化反应,得到叔酰胺。
[EN] PYRAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS<br/>[FR] COMPOSÉS PYRAZOLYLE PYRIMIDINONE UTILISÉS EN TANT QU'INHIBITEURS DE PDE2
申请人:MERCK SHARP & DOHME
公开号:WO2016154081A1
公开(公告)日:2016-09-29
The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
MONOAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
申请人:Knust Henner
公开号:US20090036422A1
公开(公告)日:2009-02-05
The present invention relates to compounds of formula
wherein
Ar, R
1
, R
2
, R
3
, R
4
, R
5
, n, o, and p are as defined herein
or to pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures thereof. The compounds of formula I can be used for the treatment of sleep disorders, such as sleep apnea, narcolepsy, insomnia, parasomnia, jet lag syndrome, circadian rhythms disorder or sleep disorders associated with neurological diseases.
[EN] COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION<br/>[FR] COMPOSÉS POUR LA RÉDUCTION DE LA PRODUCTION DE ß-AMYLOÏDE
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2012103297A1
公开(公告)日:2012-08-02
The present disclosure provides a series of compounds of the formula (I), which modulate β-amyloid peptide (β-ΑΡ) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by β-amyloid peptide (β-ΑΡ) production.